Assembly Biosciences ASMB Accrued Research And Development Expenses Current
Accrued Research And Development Expenses Current at other companies
Other financials
Where this comes from
Reported directly by Assembly Biosciences in its filing.
Tagged under the XBRL concept asmb:AccruedResearchAndDevelopmentExpensesCurrent.
The official record: Assembly Biosciences’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Assembly Biosciences's accrued research and development expenses current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Assembly Biosciences's accrued research and development expenses current?
- Assembly Biosciences (ASMB) reported accrued research and development expenses current of $1.54M in Q1 2026.
- How has Assembly Biosciences's accrued research and development expenses current changed year-over-year?
- Assembly Biosciences's accrued research and development expenses current decreased by 27.0% year-over-year, from $2.11M to $1.54M.
- What is the long-term trend for Assembly Biosciences's accrued research and development expenses current?
- Over 5 years (2020 to 2025), Assembly Biosciences's accrued research and development expenses current has grown at a -11.7% compound annual growth rate (CAGR), from $4.44M to $2.39M.
- What does accrued research and development expenses current mean?
- This metric represents the total amount of research and development costs incurred by the company for which services have been performed or goods received, but for which payment has not yet been made. It reflects short-term financial obligations related to ongoing clinical trials, laboratory studies, and drug development activities. Monitoring this balance is essential for assessing the company's near-term cash requirements and the pace of its active R&D pipeline.